艾力斯 (688578.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.4x

Market Cap

CNY 50.49B

MomentumView details →

1D Return

−3.70%

YTD Return

—

RSI (14)

44.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.4x

Market Cap

CNY 50.49B

RSI (14)

44.7

MomentumView details →

1D Return

−3.70%

YTD Return

—

ProfitabilityView details →

Gross Margin

96.31%

Net Margin

42.57%

EBITDA Margin

46.27%

ROE (TTM)

31.18%

ROA (TTM)

28.12%

Asset Turnover

0.69x

GrowthView details →

Revenue YoY

+44.95%

EPS YoY

+57.37%

FCF YoY

+78.85%

Revenue CAGR 3Y

+87.18%

EPS CAGR 3Y

+155.91%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 2.01

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.25x

Quick Ratio

5.17x

Div Yield

1.45%

Div Rate

CNY 1.60

Div Growth 1Y

+50.00%

Financials snapshotView financials →

Revenue (TTM)

5.67B

Net Income (TTM)

2.41B

Op. CF (TTM)

2.48B

Next earningsOct 26, 2026 →

Latest newsMore news →

Ailisi announced a cash dividend of 6.00 yuan per 10 shares, totaling 270 million yuan, for the first half of 2026.16d ago

Allist Pharmaceuticals forecast first-half 2026 revenue of 3.31 billion yuan and net profit of 1.54 billion yuan, up 39.44% and 46.49% year-on-year respectively, driven by furmonertinib sales.17d ago

Similar companies

Pharmaron Beijing Co., Ltd.03759.HK Asymchem Laboratories (Tianjin) Co., Ltd.06821.HK Amicogen, Inc.092040.KQ GeneOne Life Science, Inc.011000.KS RemeGen Co., Ltd.09995.HK Revolution Medicines, Inc.RVMD Find similar companies →

Latest newsMore news →

Ailisi announced a cash dividend of 6.00 yuan per 10 shares, totaling 270 million yuan, for the first half of 2026.16d ago Allist Pharmaceuticals forecast first-half 2026 revenue of 3.31 billion yuan and net profit of 1.54 billion yuan, up 39.44% and 46.49% year-on-year respectively, driven by furmonertinib sales.17d ago